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Abstract
Background: The relationship between admission triglyceride (TG) levels and long-term
outcomes has not been established in patients with acute coronary syndrome. We tested the
hypothesis that patients who develop non-ST segment elevation myocardial infarction
(NSTEMI) despite low TG have a worse cardiovascular outcome in the long term.
Methods: Patients admitted with NSTEMI between 1 January 1997 and 31 December 2000
and with fasting lipid profiles measured within 24 hours of admission were included for
analysis. Baseline characteristics and three-year all-cause mortality were compared between
the patients with TG above and below the median. Multivariate analysis was used to deter-
mine the predictors of all-cause mortality and adjusted survival was analyzed using the Cox
proportional hazard model.
Results: Of 517 patients, 395 had TG £ 200 mg/dL and 124 had TG > 200 mg/dL. Patients
with low TG were more often Caucasian, with no significant differences in gender or severity
of coronary artery disease between the two groups. There was a trend for increased all-cause
mortality at six months (9% vs 3%, p = 0.045) and three years (13.4% vs 5.6%, p = 0.016) in
patients with low TG. In multivariate analysis, low TG level at admission was an independent
predictor of increased mortality at three years (adjusted OR 2.5, 95% CI = 1.04–5.9, p = 0.04).
Conclusions: In our cohort, lower TG at admission is associated with increased three-year
mortality in patients with NSTEMI. Whether this is a result of current therapy, or a marker
for worse baseline characteristics, needs to be studied further. (Cardiol J 2011; 18, 3: 297–303)
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Introduction
Hyperlipidemia, including hypertriglyceri-
demia, has been shown to be an independent risk
factor for the development of coronary artery dise-
ase (CAD) [1–5]. Randomized controlled trials have
demonstrated that lipid-lowering therapy improves
all-cause mortality and morbidity in patients with
risk factors for, and with established, CAD [6–8].
However, many patients still develop atheroscle-
rotic complications despite being on lipid-lowering
therapy and/or having target low lipid profiles. In
randomized trials involving patients with CAD,
major adverse cardiac events (MACE) were noted
in 8–22% of patients on lipid-lowering therapy de-
spite achieving target lipid levels [6–14].
Low cholesterol and triglyceride (TG) levels
have been associated with poor prognosis in some
cardiac and non-cardiac disease states, elderly pa-
tients, cancer patients and HIV patients with low
cholesterol [15–17]. Several studies have also
shown better outcomes for both ischemic and non-
-ischemic chronic established heart failure patients
with higher cholesterol levels including serum TG,
than for patients with lower levels [18]. Among
stroke patients, low serum TG concentrations, and
not low cholesterol, independently predict poor
outcome with increased mortality [19]. We have
reported before that patients with acute coronary
syndrome despite low density lipoprotein choles-
terol (LDL) have increased three year mortality
[20]. The prognostic value of admission serum TG
has not been established in patients with acute coro-
nary syndrome. We wanted to test the hypothesis
that patients who have low TG levels at the time of
their non-ST segment elevation myocardial infarc-
tion (NSTEMI) have worse long term outcomes.
Methods
This study was approved and monitored by the
Investigational Review Board of the study hospital.
The study population consisted of consecutive pa-
tients admitted to the Coronary Intensive Care Unit
(CICU) of a tertiary care hospital between January
1997 and December 2000 with admission diagnosis
of NSTEMI, who had had their lipid profile mea-
sured within 24 hours of hospital admission. Pa-
tients whose lipid profiles were measured beyond
24 hours of hospital admission were excluded be-
cause the validity of the plasma lipid levels mea-
sured beyond 24 hours from the onset of myocar-
dial infarction has been questioned [21–26].
NSTEMI was defined as patients presenting with
chest pain suggestive of myocardial ischemia, with
positive markers of myocardial damage (creatinine
kinase-MB or troponin) and/or electrocardiographic
changes other than ST segment elevation. The diag-
nosis was made at the time of admission to the car-
diac intensive care unit. Patients with ST-segment el-
evation, new onset left bundle branch block, cardiac
arrest, and those not undergoing coronary angiogra-
phy during the hospitalization were excluded.
We included only patients undergoing angio-
graphy, in order to capture patients who had defi-
nite acute coronary syndrome and coronary artery
disease. Fasting lipid profiles including total, LDL,
high-density lipoprotein (HDL) cholesterol and trig-
lycerides that were measured in the first 24 hours
of admission were collected. Clinical variables, an-
giographic results, and outcomes were obtained
from electronic and written medical records, car-
diac catheterization laboratory data forms, and the
CICU database. The CICU database is a prospec-
tive registry of every admission to the 16-bed CICU.
The database includes 300 distinct data elements
prospectively recorded on case report forms by
trained research assistants and updated annually.
Six-month clinical outcomes were collected using
chart review. All-cause mortality data was verified
with the Social Security Death Certificate Regis-
tries with three-year follow-up.
Patients were divided into two groups accord-
ing to whether they had TG level below or above
the median TG. The primary endpoint was three-
-year all-cause mortality. The secondary endpoint
was MACE at six months. MACE was defined as
all-cause mortality, non-fatal myocardial infarction,
percutaneous coronary intervention (PCI), or coro-
nary artery bypass grafting (CABG) at follow-up.
Statistical analysis
Baseline demographic and clinical characteris-
tics were compared between groups using Student’s
t-test for continuous variables and c2 test/Fischer
Exact Test for categorical variables. Cox propor-
tional hazard analysis was used to determine the
independent predictors of all-cause mortality. In
addition, adjusted survival curves were construct-
ed and compared with Cox-regression survival ana-
lysis. Adjustment was done for both baseline vari-
ables with unequal distribution (gender, race, prior
myocardial infarction, hypertension, diabetes, lipid-
-lowering therapy, prior aspirin, beta-blockers, dias-
tolic blood pressure, and admission HDL level).
A p-value £ 0.05 was considered significant for
all analyses. Statistical analysis was done using
SPSS 11.5.
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Results
Between the beginning of 1997 and the end of
2000, of the 836 patients admitted with a diagnosis of
NSTEMI, 517 had fasting lipid profiles measured with-
in 24 hours of admission. The median TG level was
200 mg/dL, and 395 (76%) patients had TG £ 200 mg/
/dL and 124 (24%) patients had TG > 200 mg/dL.
Table 1 compares the baseline and demogra-
phic characteristics of the two groups. Patients with
low TG were more often Caucasian, but there was
no statistically significant difference in gender be-
tween the two groups. The low TG patients were
less often on lipid-lowering therapy, acetylsalicylic
acid or beta-blockers. Also, they less often had
a prior history of hypertension or diabetes melli-
tus. There was no significant difference noted in the
rate of intra-aortic balloon pump use or mechanical
ventilation use between the two groups.
All patients included in this analysis underwent
coronary angiography. There were no significant
differences in the severity of coronary artery dise-
ase between the two groups. Left ventricular (LV)
function estimates with either ventriculography or
echocardiography were also obtained for all patients.
The degree of LV dysfunction between the two
groups was significantly different, with more patients
in the low TG group having moderately to severely
depressed LV function. In addition, revascularization
therapy with PCI was not different between the two
groups; however the rates of CABG were significant-
ly lower in patients with TG £ 200 mg/dL i.e. 11%
vs 17% with a p value of 0.054 (Table 1).
The mean admission lipid profile and peak car-
diac enzymes between the two groups are shown
in Table 2. Patients who had admission TG £ 200 mg/
/dL had higher mean HDL cholesterol levels, but
the mean LDL levels were comparable. Infarct siz-
es as estimated by peak creatinine kinase levels
were comparable between the two groups, but were
significantly different when estimated by troponin
levels, with higher levels seen in the low TG group.
Table 1. Baseline characteristics.
Variable TG £ 200 mg/dL (n = 395) TG > 200 mg/dL (n = 124) P
Mean age ± SD 64 ± 12 59 ± 12 0.02
White 229 (58%) 92 (74%) 0.008
Female 156 (40%) 54 (44%) 0.40
Previous MI 116 (29%) 36 (29%) 1.00
CHF 45 (11%) 20 (16%) 0.20
Diabetes 118 (30%) 52 (42%) 0.01
Hypertension 257 (65%) 88 (71%) 0.20
Prior PCI 48 (12%) 34 (27%) < 0.001
Aspirin 158 (40%) 56 (45%) 0.31
Beta-blockers 120 (30%) 58 (47%) 0.001
Lipid-lowering medications 99 (28%) 42 (39%) 0.03
Intra-aortic balloon pump 19 (5%) 8 (7%) 0.47
Mechanical ventilation 21 (5%) 4 (3%) 0.42
PCI 210 (53%) 72 (58%) 0.33
CABG 44 (11%) 22 (17%) 0.054
LVEF: 0.033
Normal 210 (51%) 64 (52%)
Mildly depressed 74 (19%) 36 (29%)
Moderately depressed 76 (19%) 16 (13%)
Severely depressed 43 (10%) 8 (6%)
CAD stenosis: 0.40
Non obstructive 388 (10%) 7 (6%)
One vessel disease 122 (31%) 34 (24%)
Two vessel disease 93 (24%) 31 (24%)
Three vessel disease 142 (36%) 51 (41%)
TG — triglyceride; MI — myocardial infarction; CHF — congestive heart failure; PCI — percutaneous coronary intervention; CABG — coronary artery
bypass graft surgery; LVEF — left ventricular ejection fraction at the time of angiography; CAD — coronary artery disease
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There were no significant differences in MACE
between the two groups at six months, as shown in
Table 3. However, patients with TG £ 200 mg/dL
had a statistically significant higher all-cause mor-
tality at six months (9% vs 3%, p = 0.045). At three
years, patients with admission TG £ 200 mg/dL still
had a higher all-cause mortality rate compared to
patients with TG > 200 mg/dL (13.4% vs 5.6%, p =
= 0.016, odds ratio [OR] 2.6, 95% confidence in-
terval [CI] 1.2–5.8). This continued to be significant,
even after adjusting for gender, race, prior myocar-
dial infarction, hypertension, diabetes, diastolic
blood pressure, admission HDL levels, use of lipid-
-lowering therapy, prior aspirin and beta-blocker
use (OR 2.5, 95% CI 1.04–5.9, p = 0.04). The inde-
pendent predictors of all-cause mortality are shown
in Table 4. Adjusted three-year mortality curves are
shown in Figure 1.
Table 4. Independent predictors of all-cause mortality.
Variable Hazard ratio 95% confidence interval P
Diabetes 3.2 1.9–5.8 < 0.0001
Troponin elevation (per 1 mg/dL) 1.002 1.001–1.003 0.029
Triglycerides £ 200 mg/dL 2.5 1.04–5.9 0.047
Age > 65 years 2.5 1.5–4.2 < 0.0001
Adjusted for gender, race, and prior myocardial infarction, hypertension, lipid-lowering therapy, prior aspirin and beta-blocker, diastolic blood
pressure and admission HDL level
Figure 1. Kaplan-Meier curve showing mortality for pa-
tients with low triglyceride (TG) versus that for patients
with high TG over a period of three years.
Table 2. Admission lipid profile and peak cardiac enzymes.
Variable TG £ 200 mg/dL (n = 395) TG > 200 mg/dL (n = 124) P
Total cholesterol [mg/dL] 178 ± 47 207 ± 56 < 0.001
LDL cholesterol [mg/dL] 110 ± 41 110 ± 51 0.9
HDL cholesterol [mg/dL] 46 ± 14 37 ± 10 0.03
Peak creatine phosphokinase [mg/dL] 81 ± 122 62 ± 102 0.12
Peak troponin [ng/dL] 95 ± 145 64 ± 114 0.031
Table 3. Six-month outcomes.
Variable TG £ 200 mg/dL (n = 395) TG > 200 mg/dL (n = 124) P
Death (%) 34 (9%) 4 (3%) 0.045
MACE (%) 93 (24%) 24 (19%) 0.33
MI (%) 19 (7%) 6 (4%) 0.41
CABG (%) 9 (2%) 2 (2%) 1.00
PCI (%) 10 (5%) 8 (7%) 0.55
MACE — major adverse cardiac event; MI — myocardial infarction; CABG — coronary artery bypass graft surgery; PCI — percutaneous coronary
intervention;
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Discussion
This analysis demonstrates that a TG level of
£ 200 mg/dL obtained within 24 hours of admission
is associated with higher long-term all-cause mor-
tality in patients admitted with NSTEMI.
To the best of our knowledge, this is the first
study to report this observation in acute coronary
syndrome patients. This finding initially appears to
contradict current thinking about lipids and outcome
in patients with CAD. Elevated cholesterol and TG
levels have been shown to increase the risk of athe-
rosclerotic heart disease and its complications,
while lipid lowering has been shown to reduce ad-
verse cardiovascular events [6–14]. Hypertrigly-
ceridemia has been shown to be an independent risk
factor for major cardiac events, even after control-
ling for cholesterol levels [1–5]. Hypertriglyceri-
demia combined with elevated cholesterol levels
further increases the risk of cardiac events by ap-
proximately 600% [27].
However, it is possible that lower triglyceride
level at the time of a myocardial infarction in this pa-
tient population may actually identify patients with
higher long-term all-cause mortality. The two popu-
lations of low and high TG patients are inherently dif-
ferent. Although we used Cox analysis and attempt-
ed to account for all known different characteristics
between the two groups, there could have been some
other variables that we did not account for that could
have resulted in this worse long term outcome.
Another explanation for our findings could be
differences in the atherosclerotic disease pattern.
Atherosclerotic complication such as an myocardial
infarction is usually a result of multiple factors, and
lipid level is only one of the identified risk factors.
In fact, it has been recently shown that the level of
an inflammatory marker C-reactive protein be a bet-
ter predictor of worse outcome than reduction in
lipid levels after NSTEMI [28]. Seventy five per-
cent of the events are still not prevented by aggres-
sive treatment with statins to achieve LDL choles-
terol levels to £ 70 mg/dL [10]. Therefore, there
are other factors than TG levels that confer this risk
in most patients. It is possible that patients who
have a myocardial infarction in spite of a low TG
level have other risk factors that are not readily
modifiable. Thus, plaque rupture in the setting of
a low TG level may signify more complex athero-
sclerotic disease in patients with a higher risk of
long-term events.
An example of a preventative measure that may
be a marker of adverse prognosis at the time of an
event is aspirin therapy. Aspirin use is known to
reduce atherothrombotic complications in patients
with cardiovascular risk factors [29]. However, as-
pirin use within the seven days prior to an myocar-
dial infarction has been shown to be an adverse
prognosticator in patients with acute coronary syn-
drome [30]. It is believed that if atherothrombosis
develops in spite of aspirin use, this is an indicator
of a more complex plaque morphology, conferring
higher clinical risk in these patients.
Epidemiological studies have also shown that
a lower cholesterol level in general is associated
with worse outcome in patients with established
heart failure [31, 32]. The reason for this is not
entirely clear [33]. Similar findings regarding the
association of low serum cholesterol and poor out-
come have been reported for elderly individuals [34,
35] and end-stage renal failure patients undergoing
hemodialysis [36, 37]. Not much data is available
on the harmful effects of specifically low TG. Low
TG has been associated with poor outcomes for
stroke patients [19, 38].
Decreased LDL levels associated with an increase
in TG levels are often seen within a few days of myo-
cardial infarction [39]. However, in our study, lipid le-
vels were drawn within 24 hours of admission rather
than within a few days, and most patients had a low TG
level (76%), with comparable LDL levels between the
two groups to explain the difference in mortality ob-
served at three years. It is possible that low TG may
be associated with illnesses other than cardiovascular
disease that lead to higher all-cause mortality.
Hypertriglyceridemia has been shown to be the
commonest cause of low HDL cholesterol levels
[40]. However, in our study, the group with low TG
had a higher HDL level than the group with high
TG. Also the group with low TG contained a lower
percentage of people with a history of congestive
heart failure, diabetes mellitus, hypertension or PCI
in their history. However, multivariate analysis
adjusted for all the above confounding variables was
still associated with higher three-year all-cause
mortality in patients with TG £ 200 mg/dL.
Another possibility is the fact that patients with
lower TG at baseline do not get as aggressively
treated with lipid-lowering therapy. Similar trends
were seen in this study, with fewer patients being
on lipid-lowering therapy in the low TG group. This
could account for less aggressive follow-up and risk
factor modification in this group of people. Since
follow-up treatment data is not available, this can-
not be ruled out from the current analysis.
The results of our study accord with the results
of an earlier study on a similar cohort of patients.
That showed that low LDL cholesterol at the time
302
Cardiology Journal 2011, Vol. 18, No. 3
www.cardiologyjournal.org
of admission was associated with higher all-cause
three year mortality [20]. The earlier study demon-
strated that patients in the low admission LDL
study group did not have a significant difference in
the infarct size as determined by troponin levels,
neither was there a significant difference in the LV
dysfunction between the low and high admission
LDL groups. This is in contrast to our current study
findings of a significantly higher number of patients
having a larger infarct size as determined by tropo-
nin levels and moderate to severe LV dysfunction
in the low TG group as compared to the high TG
group. This potentially signifies a different under-
lying mechanism of action for TG than for LDL in
acute coronary syndrome patients that merits fur-
ther investigation.
Nonetheless, our finding that low TG at the
time of admission may be a marker for worse long-
-term outcome in NSTEMI patients is the first of
its kind. The incidence of NSTEMI is growing and
it affects more than 1.5 million patients annually in
the United States [41]. Measurement of TG on ad-
mission in these patients may have significant long-
-term prognostic implications. Instead of develop-
ing a false sense of security in patients with lower
TG, these patients may in fact need more aggres-
sive risk modification with lipid-lowering therapy,
anti-platelet agents, beta-blockers, ACE inhibitors,
smoking cessation and activity modification.
Limitations of the study
The retrospective study design, selection bias,
treatment bias and unequal distribution of baseline
co-morbidities are the major limitations of our
study. We attempted to adjust for the baseline con-
founding variables with multivariate analysis, but
may not be able to account for all confounding varia-
bles and physician/treatment effects. The effect of
myocardial infarction on the admission lipid profile
in the first 24 hours post-admission is not very well
understood. Including only those patients with
NSTEMI who underwent cardiac catheterization
could have limited the external validity of our find-
ings. In addition, therapy for the groups at follow-
up was not available and its effect on outcomes is
unclear.
Conclusions
Most patients had a TG level £ 200 mg/dL at
the time of their NSTEMI. Patients with low TG
level at the time of their myocardial infarction had
higher long-term mortality at three years. The higher
mortality persisted after adjusting for baseline dif-
ferences. Whether atherosclerotic plaque rupture in
the setting of low serum TG may be a marker of more
complex atherosclerotic disease that portends
a worse long-term prognosis in patients with
NSTEMI needs to be further explored.
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